Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(42.9%)
Phase 2
2(28.6%)
Phase 1
2(28.6%)
7Total
Phase 3(3)
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT01695187Phase 3Unknown

NB-001 Treatment of Recurrent Herpes Labialis

Role: lead

NCT01321359Phase 3Completed

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis

Role: lead

NCT00453271Phase 2Completed

Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail

Role: lead

NCT01324466Phase 3Completed

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)

Role: lead

NCT01354379Phase 1Completed

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer

Role: lead

NCT01333462Phase 1Completed

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008

Role: lead

NCT00453401Phase 2Completed

Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis

Role: lead

All 7 trials loaded